EU SmPC
Medical Information
Roche COVID-19 Response  | Questions About Our Medicines? Visit medinfo.roche.com

NEJ026 phase III trial

Combining bevacizumab with erlotinib as first-line treatment for EGFR Mut+ NSCLC resulted in a significant improvement in PFS compared with single-agent erlotinib in this patient population, which included those with asymptomatic CNS metastases.1

Study design and endpoints1

  • NEJ026 was a randomised phase III trial that took place across 69 centres in Japan.
  • The trial compared erlotinib plus bevacizumab versus erlotinib alone as first-line treatment for EGFR Mut+ NSCLC, to further evaluate the safety and efficacy of this combination observed in the JO25567 study.

ECOG PS (Eastern Co-operative Oncology Group performance status)

Key Results

Efficacy1

Patients who received erlotinib plus bevacizumab had significantly longer PFS than patients receiving single-agent erlotinib.

The results are consistent with those observed in JO25567 phase II study.2

page_31_2@2x.png
aid-kit-icon

Safety1

The grade and seriousness of AEs observed in this study were consistent with those observed in the JO25567 study.2

Please click here for further safety data

Please note; in some countries the combination of erlotinib plus bevacizumab may not be registered or reimbursed